Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $56.5 million.

  • Adma Biologics' Total Current Liabilities rose 2581.29% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 2581.29%. This contributed to the annual value of $55.5 million for FY2024, which is 1151.67% up from last year.
  • As of Q3 2025, Adma Biologics' Total Current Liabilities stood at $56.5 million, which was up 2581.29% from $74.9 million recorded in Q2 2025.
  • Adma Biologics' Total Current Liabilities' 5-year high stood at $74.9 million during Q2 2025, with a 5-year trough of $18.2 million in Q2 2021.
  • Its 5-year average for Total Current Liabilities is $42.0 million, with a median of $42.0 million in 2023.
  • Per our database at Business Quant, Adma Biologics' Total Current Liabilities skyrocketed by 9629.76% in 2021 and then tumbled by 584.93% in 2023.
  • Adma Biologics' Total Current Liabilities (Quarter) stood at $30.4 million in 2021, then rose by 29.26% to $39.3 million in 2022, then increased by 26.84% to $49.8 million in 2023, then increased by 11.52% to $55.5 million in 2024, then increased by 1.71% to $56.5 million in 2025.
  • Its last three reported values are $56.5 million in Q3 2025, $74.9 million for Q2 2025, and $53.5 million during Q1 2025.